


# Priority and watchlist medicines for in-licensing by the Medicines Patent Pool



## HIV

lenacapavir *Gilead*

broadly neutralising antibodies for HIV post-natal prophylaxis

*Multiple patent holders*

cabotegravir & rilpivirine *ViiV & Janssen*

doravirine *MSD*

islatravir *Merck*



## TUBERCULOSIS

quabodepistat *Otsuka*

BTZ-043 *Univ. of Munich & DZIF*

delpazolid *LegoChem BioSciences*

ganfeborole *GSK*

macozinone *EPFL*

sudapyridine *Shanghai Jiatan Biotech*



## PANDEMIC & EPIDEMIC THREATS

baloxavir marboxil *Roche*



## VIRAL HEPATITIS

bulevirtide *Gilead*



## DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS

Incretin-based therapies (incl. GLP1 RA)

*Multiple patent holders*

including semaglutide *Novo Nordisk*

tirzepatide *Eli Lilly*

cardiovascular fixed-dose combination therapies

*Multiple patent holders*



## CHILDHOOD ONSET DISEASES

RESPIRATORY SYNCYTIAL VIRUS

nirsevimab *Astrazeneca/Sanofi*

clesrovimab *MSD*

SICKLE CELL DISEASE

voxelotor *Pfizer*

CYSTIC FIBROSIS

elexacaftor/tezacaftor/ivacaftor *Vertex*



## ONCOLOGY

### LUNG CANCER

aumolertinib

*Revolution Medicines*

osimertinib *Astrazeneca*

adagrasib *Mirati*

lazertinib *Janssen*

sotorasib *Amgen*

### BREAST CANCER

abemaciclib *Eli Lilly*

ribociclib *Novartis*

trastuzumab SQ

*Roche*

### HAEMATOLOGICAL MALIGNANCIES

ibrutinib *Janssen*

zanubrutinib

*Beigene*

### PROSTATE CANCER

apalutamide *Janssen*

darolutamide

*Bayer*

### MULTIPLE CANCER INDICATIONS

Immune checkpoint inhibitors

*Multiple patent holders*

including pembrolizumab *MSD*

oral paclitaxel / encequidar

*Athenex*

PRIORITY LIST

WATCHLIST

JUNE 2024